HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients (Q70577149)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 January 1993

Language	Label	Description	Also known as
English	HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients	scientific article published on 01 January 1993

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Elisabeth de Vries

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

author name string

R A Janssen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

J Buter

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

E Straatsma

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

A A Heijn

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

D T Sleijfer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

N H Mulder

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

T H The

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

L de Leij

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

publication date

1 January 1993

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

36

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

198-204

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose regimen of interleukin-2 for metastatic renal carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The interleukin-2 T-cell system: a new cell growth model.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8439981

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01741092

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8439981%20AND%20SRC:MED&resulttype=core&format=json

12 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q70577149&oldid=2218927508"